Literature DB >> 28965956

Confirming cross-protection of bivalent HPV vaccine.

Julia M L Brotherton1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28965956     DOI： 10.1016/S1473-3099(17)30539-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study.

Authors:  Emi Naslazi; Jan A C Hontelez; Steffie K Naber; Marjolein van Ballegooijen; Inge M C M de Kok
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-04-09       Impact factor: 4.090

2.  Letter-to-the-Editor in response to "Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001."

Authors:  Martin Ryser; Adrienne Guignard; Valérie Berlaimont
Journal:  Papillomavirus Res       Date:  2017-12-20

3.  Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.

Authors:  Nicolas Folschweiller; Ulrich Behre; Marc Dionne; Paolo Durando; Susanna Esposito; Linda Ferguson; Murdo Ferguson; Peter Hillemanns; Shelly A McNeil; Klaus Peters; Brian Ramjattan; Tino F Schwarz; Khuanchai Supparatpinyo; Pemmaraju V Suryakirian; Michel Janssens; Philippe Moris; Annabelle Decreux; Sylviane Poncelet; Frank Struyf
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

4.  Cervical intraepithelial neoplasia grade 3 in a patient following Gardasil vaccination.

Authors:  Bruce McLucas; Eric Vail; Katherine Jane Chua; Gabriel Walt
Journal:  BMJ Case Rep       Date:  2019-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.